研究人员评估 FMPV-1/GM-CSF 疫苗在健康受试者中的安全性和免疫原性，发现其耐受性良好且能诱导免疫反应，为相关癌症治疗提供依据。 一、研究背景 癌症，这个人类健康的 “头号杀手”，一直以来都让无数患者和家属陷入绝望的深渊。在众多癌症类型中 ...

Granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as Colony Stimulating Factor 2 (granulocyte-macrophage), is a cytokine originally identified for its role in promoting the ...

为解决复发或难治性高危神经母细胞瘤治疗难题，西班牙巴塞罗那圣琼德乌医院的研究人员开展 Naxitamab 联合 GM-CSF 的 2 期临床试验。结果显示该疗法有效且安全，为患者带来新希望，推荐科研读者阅读。 西班牙巴塞罗那圣琼德乌医院（Hospital Sant Joan de Déu ...

纽约 - 专注于癌症治疗的生物制药公司Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB )宣布了naxitamab联合GM-CSF治疗高危神经母细胞瘤的二期临床试验中期结果。发表在《自然通讯》上的研究显示，该治疗方案具有显著的疗效和可控的安全性。根据 InvestingPro 数据，Y-mAbs目前市值为$249 ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has introduced the aPAP ClearPath Dried Blood Spot (DBS) Test in the United States ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

Y-mAbs Therapeutics (YMAB) announced the publication of interim data from a Phase 2 clinical trial evaluating naxitamab with ...